| Sunday |
Monday |
Tuesday |
Wednesday |
| Registration |
Parallel Symposia
• The era of personalised
health
care: Impact on drug discovery and development?
•
Is gene/protein delivery delivering?
• Can ADME and
PK be predicted
from in silico/in vitro data?
n Metabolomics: What are
the opportunities for biomarker discovery?
• What
benefits does Process
Analytical Technology (PAT) bring to the design and assurance
of product quality?
• What have we learnt from
recent safety cases for new drug development? |
Parallel Symposia
• Druggability: A
concept that will
fill the pipeline?
• Drug targeting: How successful
are we?
• What is the state-of-the-science in receptor
site modelling?
• What’s new in methods of
measuring human drug response?
• In silico
product development from molecule to man: Dream or reality?
• Nutraceuticals: Are new methods
of evaluating risk/benefit required? |
Parallel Symposia
• How to manage drug
therapy at
the extremes of age?
• How can nanotechnology and
materials science solve drug delivery problems?
•
How important is genetic and
physiological variability in drug transporters?
•
Systems biology: A driver of drug discovery and development?
• How to engineer desired particle
properties for drug delivery?
• Off-label use of medicines:
Abuse or a vehicle for innovation? |
| |
Posters
& Exhibition & Lunch |
Opening
Session |
Keynote Presentations
• What are the
main challenges for world health? What should be done now and
in the future?
• Transforming ‘art’ into
‘science’ in dosage form design – achievements
and challenges |
Keynote Presentations
• Are we meeting
the challenges
of resistance to anti-infective drugs and of newly emerging
infectious diseases?
• Will novel approaches to the
treatment of cardiovascular disease prove highly effective? |
Keynote Presentations
• Drug resistance
in cancer
chemotherapy
• Recent progress in prion biology |
| |
Round Table Discussions
• Science or
business as the driver of new drug development?
•
Does regulation help to ’innovate’ or ’stagnate’
drug development?
• How can the bioavailability of
poorly absorbed compounds be enhanced? |
Round Table Discussions
• Translational
science: A solution to the productivity gap?
• Can
microdosing accelerate drug development?
• When is
a human bioequivalence
study not needed? |
Round Table Discussions
• What is the
value of observational data post-marketing to assess safety
and efficacy?
• Life-style drugs: A new burden to
the health system?
• Is there a consensus on guidelines
for the evaluation of biosimilars? |
| |
Parallel Symposia
• Pharmacogenetics
at the bedside?
• What will be the impact of cell-
based therapy?
• Simulation and modelling in drug
development improves decisions, saving time and money?
•
Dirty vs. selective drugs in the
CNS?
• How will developments in
chemical methods sustain pharmaceutical industrial development?
• How effective is the
globalisation/harmonisation of
pharmacovigilance? |
Parallel Symposia
• Drug-drug interactions:
Avoid or
understand?
• What is the future of smart,
feedback, on-demand drug delivery systems?
• How are
disease and PK-PD
connected?
• Have omics technologies improved the
chance for successful drug development?
• Are pharmaceutical
manufacturing
technologies in stagnation?
• Are we using the right
outcome
measures to ascertain patient benefit from drug therapy? |
Parallel Symposia
• Is the patient taking
the tablets?
• Developing biotech products:
What are the challenges and solutions?
• Control of
intracellular
pharmacokinetics: Advantages for drug therapy?
• Molecular
targeting in cancer
chemotherapy?
• Miniaturisation in analytical
methods: Is small always beautiful?
• Counterfeiting
of medicines:
Detection and prevention? |
| |
Round Table Discussion
• Proactive risk
management (plans): Where are we? |
|
 |
| |
Short
Break |
| |
EUFEPS Afternoon Sessions
• Strategic,
innovative and critical
drug research initiatives: One year later
• Pharmaceutical
sciences research training and education: Needs and supply
• The EU Microdosing AMS
Partnership Programme (EUMAPP)
• The European Pharma
Sciences
Leadership Forum (EuPSLF)
• Pharmaceutical sciences
in
silico learning systems: Value and availability |
EUFEPS Afternoon Sessions
• European
drug development
centres and European growth areas
• Reformulation
of old drugs: Life
cycle management
• Vaccine delivery
• PharmacoGenetics
&
PharmacoGenomics Workshop: Outcomes and plans
• How
to start up a new company?
• Drug product quality
after new
legislation |
| Exhibition Opening and Welcome Reception |
|
Congress Dinner |
